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Abstract. TBX15 is a gene involved in the development 
of mesodermal derivatives. As the ovaries and the female 
reproductive system are of mesodermal origin, the aim of 
the present study was to determine the methylation status of 
the TBX15 gene promoter and the expression levels of TBX15 
in ovarian carcinoma, which is the most lethal and aggres-
sive type of gynecological tumor, in order to determine the 
role of TBX15 in the pathogenesis of ovarian carcinoma. 
This alteration could be used to predict tumor development, 
progression, recurrence and therapeutic effects. The study was 
conducted on 80 epithelial ovarian carcinoma and 17 control 
cases (normal ovarian and tubal tissues). TBX15 promoter 
methylation was first determined by pyrosequencing following 
bisulfite modification, then by cloning and sequencing, in 
order to obtain information about the epigenetic haplotype. 
Immunohistochemical analysis was performed to evaluate 
the correlation between the methylation and protein expres-
sion levels. Data revealed a statistically significant increase of 
the TBX15 promoter region methylation in 82% of the tumor 
samples and in various histological subtypes. Immunohisto-
chemistry showed an inverse correlation between methylation 
levels and the expression of the TBX15 protein. Furthermore, 
numerous tumor samples displayed varying degrees of intra-
tumor heterogeneity. Thus, the present study determined that 
ovarian carcinoma typically expresses low levels of TBX15 
protein, predominantly due to an epigenetic mechanism. This 
may have a role in the pathogenesis of ovarian carcinoma 
independent of the histological subtype.
Introduction
Ovarian cancer is the fourth most common type of cancer in 
the female genital tract, but has the highest mortality rate of 
all gynecological tumors. Ovarian carcinoma accounts for 
>90% of cases of ovarian cancer and may arise from relatively 
pluripotent cells of the coelomic epithelium or ‘modified meso-
thelium’ that covers the ovary (1). The coelomic epithelium is 
the mesodermal-derived epithelial lining of the intraembryonic 
coelom that invaginates to give rise to the mülllerian ducts, the 
primordia for the epithelia of the fallopian tube, the endometrium 
and the endocervix (1). There is now compelling evidence that 
certain carcinomas can also originate from the fallopian tubes 
and the endometriosis (1,2). Ovarian carcinoma are a heteroge-
neous group of neoplasms that exhibit a wide range of tumor 
morphologies and clinical manifestations (2). According to the 
World Health Organization classification, the most common 
tumor subtypes are serous, endometrioid and mucinous, and are 
characterized by their morphological resemblance to various 
mucosal tissues of the female reproductive tract (3). Cytoge-
netic and molecular analysis indicates that multiple genetic and 
epigenetic changes are involved in the pathogenesis of ovarian 
carcinoma (2,4); however, it remains unclear how these alterations 
lead to the development of ovarian cancer. Better understanding 
of the molecular mechanisms responsible for the different 
types of ovarian cancer may improve diagnosis and treatment 
according to the biological characteristics of the cancer.
T-box genes constitute a family encoding transcription 
factors characterized by a highly conserved DNA-binding 
region, the T-box. These genes have a role in regulating the 
proliferation and differentiation of tissue‑specific stem and 
progenitor cells during organogenesis (5,6). Previous studies 
have indicated that altered T-box gene expression may be 
associated with human cancer (7-10). For example, TBX15, 
a member of the T-box family, appears to be involved in 
mesodermal differentiation (11,12), putatively through its 
interaction with co-repressors of the Groucho family (13) 
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and, therefore, modulation of the Notch, Wingless/Wnt and 
decapentaplegic/bone morphogenetic protein/transforming 
growth factor-β signaling pathways (14). Furthermore, TBX15 
hypermethylation was observed in prostate carcinoma and 
may be correlated to a negative prognosis (15,16).
As stated, the TBX15 gene is involved in mesodermal differ-
entiation. Furthermore, the ovary and the female reproductive 
system are of mesodermal origin. Therefore, the present study 
analyzed the TBX15 gene, in particular the epigenetic alteration 
of the TBX15 gene promoter, in ovarian carcinoma in order to 
investigate its role in the pathogenesis of this neoplasia. This 
alteration could be used to predict tumor development, progres-
sion, recurrence and therapeutic effects. First, the percentage 
of DNA methylation at CpG sites was determined by bisul-
fite‑pyrosequencing, as well as by cloning and sequencing, to 
refine the methylation pattern at the level of individual DNA 
molecules. Second, immunohistochemistry was performed 
to determine the correlation between DNA methylation and 
expression of the TBX15 protein. Differences between the 
subtypes of ovarian carcinoma, and a possible correlation to 
pathological parameters and prognosis were also investigated.
Materials and methods
Patients and tissues. The present study was conducted on 
tissues obtained from ovaries removed surgically from 
women with ovarian carcinoma who were not subjected to 
preoperative chemotherapy. For control cases, 17 normal 
ovarian and tubal tissues were obtained from women treated 
surgically for benign gynecological conditions with no 
evidence of cancer (median age, 58 years). The 80 tumor 
samples included 29 serous, 23 mucinous and 28 endometrioid 
carcinomas, the three most frequent subtypes of carcinoma. 
All tissues were obtained via total abdominal hysterectomy 
and bilateral salpingo-oophorectomy performed between 
January 1995 and April 2010 at Pathological Anatomy Unit 
of the University of Modena and Reggio Emilia (Modena, 
Italy). For cases of mucinous carcinoma, a careful evalua-
tion of the clinical history, in search of a primary mucinous 
carcinoma at another site, was performed, and these types of 
patients were excluded. Furthermore, cases with immunohis-
tochemical positivity for CDX2, CEA or CK20, or negativity 
for CA125 were excluded from the study. The clinical and 
pathological features of patients are summarized in Table I. 
The stage was established according to the International 
Federation of Gynaecology and Obstetrics criteria (17). The 
pathological grade was specified according to the Silverberg 
grading system (18) for all tumors excluding serous tumors. 
For serous tumors, low and high grade were determined 
according to the proposed 2-tier grading system (19). Recur-
rences, metastasis and survival were established by the 
investigation of clinical files and pathological reports of 
patients. The study was approved by ethics committee of 
The University of Modena and Reggio Emilia and written 
informed consent was obtained from all patients.
Tissues were formalin-fixed and paraffin-embedded, 
sectioned at 3-4 µm, stained with hematoxylin and eosin, 
and reviewed by two pathologists (Professor Lorena Losi and 
Professor Francesco Rivasi) in order to confirm the histo-
pathological diagnosis.
Microdissection, DNA extraction and bisulfite conversion. 
Deparaffinized and rinsed sections (OTTIX and alcohol; 
Diapath S.P.A, Bergamo, Italy) were stained in 0.1% toluidine 
blue for 30 sec, washed, air-dried and manually microdissected 
using a scalpel blade under a microscopic by a pathologist 
(Professor Lorena Losi), in order to enrich the samples to at 
least 75% tumor cells. DNA extraction was performed using a 
Maxwell 16 FFPE Tissue LEV DNA Purification kit (Promega 
Corporation, Madison, WI, USA), according to the manufac-
turer's instructions and 100 ng genomic DNA was subjected 
to bisulfite conversion using the EpiTect Bisulfite kit (Qiagen, 
Hilden, Germany), according to the manufacturer's protocol.
Methylation analysis by pyrosequencing. Bisulfite‑modified 
genomic DNA was PCR-amplified using specific primers 
covering two consecutive regions of the human TBX15 
promoter (2.8 kb upstream of the transcription start site of 
NM_152380.2), as previously described (20). The primers were 
as follows: Forward, 5'-ATG GGA TAG TAT AAT TGA TTT 
GGA ATTT-3' and reverse, 5'-AAA AAC CTT TCA CCC CCA 
TAA-3' for the upstream region (Amp1); and forward, 5'-GGT 
ATT GGG GTA AGA GGA GA-3' and reverse, 5'-ACC ACA CAA 
AAC TCC CTT TAT-3' for the downstream region (Amp2). 
Both reverse primers were biotinylated at the 5'-end. PCR was 
performed using 3 µl of DNA, MgSO4 at a final concentration 
of 3 mM and each primer at a final concentration of 0.25 µM 
using 0.1 U of Platinum Taq DNA Polymerase (Invitrogen; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA). PCR was 
performed for a total of 41 cycles at an annealing tempera-
ture of 60˚C. The primers of the reference gene GAPDH 
were: Forward, 5'-AAG GTG AAG GTC GGA GTC AAC-3' and 
reverse, 5'-GAG TTA AAA GCA GCC CTG GTG-3'.
The DNA methylation status of the two regions was 
assessed by pyrosequencing using the automated system 
PyroMark Q24 (Qiagen). Sequencing primers were designed 
using the PyroMark Assay Design SW software (version 2.0; 
Qiagen), as follows: Upstream, 5'‑GAG GGA GTG GAT TTT‑3' 
and downstream, 5'-GGA AGT TTA GAT TTT ATA TTT 
GTGA‑3'. The results were analyzed using Pyromark Q24 
software (version 2.0.6; Qiagen) to estimate the percentage 
of methylation at each CpG position for Amp1 (n=1,..9) and 
Amp2 (n=1,…10). Samples were categorized as follows: 
<40%, low level of methylation; 40-70%, medium level of 
methylation; and >70% very high level of methylation.
Methylation analysis by cloning and sequencing. The PCR 
products (Amp1 and Amp2) were ligated into a pGEM-T 
Vector (Promega Corporation), according to the manufac-
turer's protocol. The ligation products were transformed into 
chemically competent JM109 bacteria (Promega Corpora-
tion), according to the manufacturer's protocol. In total, 100 µl 
mixture was plated on agar plates containing ampicillin, 
X-gal and isopropyl thio-β-D-galactoside for blue-white 
screening. The plates were incubated at 37˚C overnight. 
Finally, DNA was extracted from 15-20 bacterial colonies, 
and subjected to PCR amplification of Amp1 and Amp2 
followed by analysis by pyrosequencing. Cloning‑sequencing 
data was then analyzed using BiQ Analyzer software 
(http://biq‑analyzer.bioinf.mpi‑inf.mpg.de/) to generate 
corresponding lollipop methylation diagrams (21).
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Immunohistochemical analysis. Immunohistochemical 
analysis of TBX15 was conducted on all 80 formalin‑fixed, 
paraffin-embedded neoplastic tissue samples and all 
control samples. Immunohistochemistry was performed 
on a representative tumor sample in which, in addition to 
neoplasia, there was a marginal region of normal ovarian 
tissue, which was sectioned at 4 µm. The normal controls 
are referred to tissues of different patients without ovarian 
carrcinomas.   Immunohistochemistry was performed using 
a TBX15 rabbit anti-human polyclonal (C-terminus) primary 
antibody (catalog no., LS-C81114-100; dilution, 1:100; 
LifeSpan Biosciences, Inc., Seattle, WA, USA) with a Bench-
Mark XT automated staining system (Ventana, Strasbourg, 
France), using 3,3'-diaminobenzidine as the chromogen. The 
secondary antibody was included in the Ultraview kit (catalog 
no., 05269806001; Roche Diagnostics Spa, Milan, Italy), 
which was used according to the manufacturer's protocol. At 
the end of reaction, slides were counterstained with hema-
toxylin. Primary antibody incubation was 37˚C for 1 h.
Statistical analysis. Explorative and inferential data 
analysis was performed using R program version 3.2.2 
(www.R-project.org/) with the following added packages: 
Dplyr, reshape2, data.table, extraGrid and ggplot2. One-way 
analysis of variance (ANOVA) followed by Tukey's honest 
significant difference (HSD) multiple comparisons of means 
were applied to analyze the difference in mean methylation 
between histotypes in all CpGn sites, for Amp1 (n=1,..9) and 
Amp2 (n=1,…10) regions. Immunohistochemistry results 
were analyzed by two methods: i) Results were primarily 
analyzed by linear regression between mean methylation of 
pathological histotypes over all CpG sites and corresponding 
immunohistochemistry for Amp1, Amp2, and the mean of 
Amp1 and Amp2; ii) results were also analyzed by the χ2 test 
to verify possible associations between pathological features 
(grade and stage), patient status (overall and disease-free 
survival) and the methylation values of pathological histo-
types (split in two groups by thresholds of ≤40% and >40% 
methylation). Data was analyzed from three independent 
experiments. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Quantitative analysis of TBX15 promoter methylation at 
multiple CpG sites by pyrosequencing. Methylation levels 
of 19 CpG sites within the 5'-region of the TBX15 gene were 
analyzed by bisulfite pyrosequencing in 80 ovarian tumor 
samples and 17 control samples. In normal ovarian tissues, 
a mean methylation level range of 10-30% was observed 
in all the 17 samples at all 19 CpG sites analyzed; this is 
considered to be a low level of methylation (Fig. 1A and B). 
For both TBX15 promoter regions investigated (Amp1 and 
Amp2), a significant increase in mean methylation (range, 
30-80%) was observed in the different groups of ovarian 
cancer compared with controls (N) at all the 19 CpG sites, 
as shown from Tukey's HSD post‑hoc comparisons of means 
(Fig. 2A and B). For the upstream region of the promoter 
(Amp1), the endometrioid carcinoma samples showed a higher 
mean percentage of methylation than the serous and mucinous 
carcinoma samples for all the analyzed CpG positions; in 
particular, with the methylation values for CpGs 1, 2, 3, 4, 5, 
6, 7, 9 of the serous histotype (E-S, y-axis; Fig. 2A) and CpGs 
1, 4 and 5 of the mucinous histotype reached statistical signifi-
cance compared with endometrioid carcinoma (E-M, y-axis; 
P<0.05; Fig. 2A). By contrast, no significant difference was 
noted when comparing serous and mucinous cases. Similarly, 
the ANOVA and Tukey's HSD analysis revealed differences 
in the methylation profile of the downstream region (Amp2) 
between the three tumor groups. Again, endometrioid carci-
nomas showed the highest mean percentage of methylation. 
When considering the CpG positions individually, mucinous 
tumors presented significantly lower methylation levels at 
CpG sites 5 and 7 compared with serous carcinomas, whereas 
for endometrioid methylation was significantly increased at 
CpG position 1 compared with both mucinous and serous 
carcinomas (mucinous, P=0.008; serous, P=0.040; Fig. 2B). 
Considering all the 19 CpG sites (9 and 10 CpG sites for the 
Amp1 and Amp2, respectively), the mean ± standard devia-
tion methylation was 19.21±2.95% for the control group, while 
the means were 50.56±16.28, 50.48±15.08 and 63.27±15.56% 
for serous, mucinous and endometrioid subtypes, respectively 
(Fig. 3). Unlike control samples, tumor samples exhibited a 
wider distribution of TBX15 promoter methylation percentages, 
ranging from cases showing a methylation percentage similar 
to control samples to cases with methylation reaching almost 
100%. Notably, when calculating the median of the methyla-
tion percentage for each group, the values were close to the 
mean of each group (49.7, 50.9 and 63.5% for serous, mucinous 
and endometrioid subtypes, respectively), demonstrating that 
the distribution of the observed methylation percentages was 
considerably homogenous within each group (Fig. 3).
TBX15 promoter methylation patterns of individual clones. 
To assess the methylation profile of the TBX15 promoter at 
the single molecule level, a cloning‑sequencing procedure 
Table I. Clinical and pathological features of ovarian carcinoma.
 Histological grade Stage
 ----------------------------------------------------------------- -----------------------------------------
Neoplasia Patients, n Median age, years Low High I II III I II III IV
Serous carcinoma 29 57 5 24 - - - 6 5 17 1
Mucinous carcinoma 23 59 - - 13 4 6 19 1 3 0
Endometrioid carcinoma 28 61 - - 14 8 6 22 3 3 0
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was performed on the Amp1 and Amp2 PCR products. The 
control cases, with a mean percentage of methylation of ~20%, 
exhibited methylation in only a small number of CpG sites in 
the Amp1 and Amp2 regions. Indeed, the mean methylation of 
the Amp1 and Amp2 regions was 15, 20 and 17% for N5, N6 
and N17, respectively, (Fig. 4). 
For tumor samples, both regions (Amp1 and Amp2) 
were found to be either fully (or almost fully) methylated 
or contained only a small number of methylated CpG sites, 
as in normal tissues. Therefore, at the single molecule level, 
the TBX15 promoter exhibited either low or high methylation 
in ovarian carcinoma samples. When tumor samples were 
analyzed more in detail, a marked association was observed 
between the mean methylation level measured by pyrose-
quencing and the percentage of molecules with either fully (or 
almost fully) methylated Amp1 and Amp2 regions. This obser-
vation is illustrated in Fig. 4, with three serous tumor samples 
that exhibited different mean levels of TBX15 methylation. 
Similar results were obtained with mucinous and endometrioid 
carcinomas (data not shown). For the S2 tumor sample with 
strong hypermethylation (80 and 91% for Amp1 and Amp2, 
respectively), as expected, almost all the molecules were 
methylated in almost all CpG sites. The S1 sample, which 
had an intermediate level of methylation (76 and 53% for 
Amp1 and Amp2, respectively), had a mixture of molecules, 
some with sporadic methylation, such as in the controls, and 
Figure 1. Methylation percentage of each CpG site within the (A) Amp1 and (B) Amp2 regions of the TBX15 promoter gene. For both TBX15 promoter regions 
investigated (Amp1 and Amp2), a meaningful increase in methylation was observed in the different groups of ovarian carcinoma (S, M and E) compared 
with the controls (N) at all 19 CpG sites, 9 for Amp1 and 10 for Amp2. Box plots indicate the first and third quartiles, median, and upper and lower quartiles 
(whiskers). Outliers are indicated by empty circles and mean values are indicated by black circles. Data are also presented as mean ± SE. SE, standard error; 
N, normal; S, serous; M, mucinous; E, endometrioid.
  A
  B
ONCOLOGY LETTERS  12:  2811-2819,  2016 2815
some molecules that were heavily or even fully methylated 
(Fig. 4). For the S3 serous sample with mild methylation (37 
and 13% for Amp1 and Amp2, respectively), the situation 
was similar to that in the controls except that the number of 
methylated CpG sites was marginally higher. According to all 
the results obtained, hypermethylation of the TBX15 promoter 
should be considered when mean methylation of at least 40% 
is observed in the Amp1 or Amp2 region. In the current study, 
pyrosequencing revealed that hypomethylation occurred in all 
17 control ovary samples and in 15 ovarian carcinoma samples. 
Figure 2. Results of one way analysis of variance followed by Tukey's HSD multiple comparisons test. Difference of % methylation values (x‑axis) and cor-
responding 95% CI (horizontal bars) between normal and histotype group means are shown for all the possible histotype couples (y-axis) in CpG sites (y-axis) 
for (A) Amp1 and (B) Amp2. The vertical dashed line indicates zero difference. CI crossing dashed line shows non significant difference for the corresponding 
couple of patients type. All histotype couples with a non‑zero crossing CI present a significant % methylation difference with P<0.05 in a range of <0.005‑0.031 
for AMP1 and <0.005‑0.046 for AMP2. The shorter the distance of CI from zero, the larger the P‑value. HSD, honest significant difference; N, normal; S, 
serous; M, mucinous; E, endometrioid; CI, confidence interval.
  A
  B
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TBX15 hypermethylation was observed in 65/80 (82%) cases 
of ovarian cancer, in particular in 83, 74 and 88% of serous, 
mucinous and endometrioid carcinomas, respectively.
Immunohistochemical expression of TBX15. To determine if 
TBX15 promoter methylation could be a mechanism for gene 
silencing, TBX15 protein expression was analyzed by immuno-
histochemistry. In the control cases, TBX15 protein was present 
in the nucleus of the ovarian mesothelium, stromal cells and 
vascular smooth muscle cells (Fig. 5A). Immunohistochemical 
positivity was also present in the epithelium of the fallopian 
tubes.
Figure 4. Lollipop methylation diagram showing DNA methylation of the Amp1 and Amp2 regions of the TBX15 promoter gene at the molecular level. 
Amplification, bisulfite‑pyrosequencing and cloning of the Amp1 and Amp2 regions was performed on genomic DNA extracted from control ovarian (N5, N6, 
N17) and carcinoma (S1, S2, S3) samples. A small number of methylated CpG sites (black circles) were observed in control tissues, whereas hypermethylation 
was observed in a large proportion of S1 and S2 samples. N, normal; S, serous; M, mucinous; E, endometrioid.
Figure 3. Mean DNA methylation of the Amp1 and Amp2 regions of the TBX15 promoter gene. The mean DNA methylation of each case is represented by 
a triangle. The tumor samples (S, M and E) showed a wider distribution of TBX15 promoter methylation percentages, ranging from methylation percentage 
similar to that in control samples, to cases with methylation close to 100%. Box plots indicate the first and third quartiles, median, and upper and lower quar-
tiles (whiskers). Outliers are indicated by empty circles and mean values are indicated by black circles. Data are also presented as mean ± standard deviation. 
S, serous; M, mucinous; E, endometrioid.
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For all the neoplastic samples with a low level of methyla-
tion (<40%), the presence of TBX15 expression was observed 
in almost all the tumor cells (Fig. 5B). By contrast, an absence 
of TBX15 protein expression was observed in almost all the 
tumor cells in samples with a very high level of methylation 
(>70%; Fig. 5C). Notably, in samples with a medium level 
of methylation (40-70%), only some focal regions exhibited 
TBX15 protein expression (Fig. 5D). Therefore, in ovarian 
tumor samples, an inverse correlation was observed between 
the level of TBX15 promoter methylation and the expression of 
the TBX15 protein (r=-0.7 for Amp1; r=-0.8 for Amp2; r=-0.83 
for the mean between the two regions; P<0.01; Fig. 6). The two 
regions, Amp1 and Amp2, present a comparable correlation 
coefficient, suggesting that both regions may be involved in the 
silencing of the gene.
Correlation of TBX15 methylation with clinical and patho-
logical parameters. The possible association of methylation 
Figure 5. Immunohistochemical expression of the TBX15 protein in normal and neoplastic ovarian tissue samples. (A) Normal ovarian tissue with positive 
staining of TBX15 in the nucleus of the ovarian mesothelium and in cortical stromal cells (magnification, x10). Endometrioid carcinomas with different levels 
of TBX15 promoter methylation: (B) 20%, (C) 72% and (D) 53% (magnification, x20). 3,3'‑diaminobenzidine and hematoxylin staining.
Figure 6. Linear regression between promoter methylation and IHC of TBX15 for Amp1, Amp2 and the mean of Amp1 and Amp2. The linear regression 
performed in ovarian tumor samples shows an inverse correlation between the level of TBX15 promoter methylation and the expression of the TBX15 protein, 
as determined by IHC (r=‑0.7 in Amp1, r=‑0.8 in Amp2, r=‑0.83 for the mean between the two regions; P<0.01 for both line coefficients, in all three lines). S, 
serous; M, mucinous; E, endometrioid; IHC, immunohistochemistry.
  A   B
  C   D
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results with pathological and clinical features, such as grade, 
stage, overall survival and disease-free survival, was inves-
tigated. When cases with >40% mean methylation were 
considered to be methylated, the χ2 test showed that all consid-
ered parameters were independent of TBX15 methylation 
status (data not shown).
Discussion
In the current study, the methylation status of the TBX15 
promoter gene and its protein expression were investigated in 
order to determine its role in the pathogenesis of ovarian carci-
noma according to its implication in mesodermal tissues, such 
as the ovary and the other organs of the reproductive system. 
In normal ovarian tissues, the TBX15 methylation level was 
low and varied between 10-30% at a single CpG site. Notably, 
hypermethylation of the TBX15 promoter was observed in 
82% of the total ovarian carcinoma samples, with similar 
percentages in various histological subtypes.
The analysis of TBX15 expression by immunohistochem-
istry confirmed the correlation between promoter methylation 
and the loss of TBX15 expression in ovarian carcinoma. 
Therefore, DNA methylation may be the primary mechanism 
responsible for TBX15 gene silencing in ovarian carcinoma. 
Intratumor heterogeneity was noted by immunohistochemistry 
and was confirmed by methylation analysis in approximately 
half of the ovarian cancer cases. In the present study, the 
analyzed tumor samples were enriched to at least 75% tumor 
cells by manual microdissection. The mean methylation level 
of tumor samples ranged between 30 and 80%, which indi-
cates that, for some of the carcinoma samples, only certain 
tumor cells harbored a hypermethylated TBX15 promoter. 
Additional information regarding the methylation status was 
obtained by bisulfite sequencing after the cloning of PCR 
products, which revealed that, in all normal ovarian tissues 
and in ~15% of cancer tissues, CpG methylation was randomly 
distributed over the region and no fully methylated molecules 
were detected. By contrast, in neoplastic samples, the mean 
increase in methylation compared with the controls resulted in 
fully or almost fully methylated molecules. Overall, methyla-
tion analysis revealed heterogeneity at CpG sites and between 
individual molecules. The presence of hypomethylated and 
hypermethylated clones in various ovarian tumor samples may 
be associated with the presence of normal stromal cells, tumor 
cells at various stages of progression towards tumorigenesis, 
or populations of tumor cells subject to clonal evolution. This 
observation is in accordance with genetic or epigenetic intratu-
moral heterogeneity, as previously observed in colorectal (22), 
breast (23) and ovarian (24) cancer.
To date, the role of TBX15 in neoplastic diseases remains 
unknown; however, a previous study identified aberrant 
methylation of TBX15 in prostate carcinoma, highlighting its 
possible role as a prognostic marker. Indeed, TBX15 methyla-
tion was found to be associated with the pathological stage and 
Gleason score in prostate carcinoma (16), suggesting that 
TBX15 may be useful as a methylation marker in pre‑ and 
post-treatment clinical evaluations. In the present study, no 
correlation was identified between TBX15 methylation and 
the stage or grade of ovarian carcinoma. Furthermore, the 
overall and disease-free survival rates did not appear to be 
associated with the methylation and immunohistochemical 
data. This lack of correlation may be due to the presence of 
intratumor heterogeneity in ovarian tumors, which confounds 
the validation of single biomarkers, or, more likely, because 
this epigenetic alteration occurs in the majority of ovarian 
carcinoma cases. It would be useful for future studies to 
determine whether hypermethylation of TBX15 could be used 
to predict tumor development, progression and therapeutic 
effects in ovarian carcinoma.
A previous study observed that specific T-box genes 
promote epithelial-mesenchymal transition (EMT) in 
neoplastic cell lines and even in certain neoplasia. This 
process involves events that convert adherent epithelial 
cells into individual migratory cells that can invade the 
extracellular matrix; such cells may be critical for cancer 
progression and the development of metastasis (25). Further-
more, an association between cells undergoing EMT and 
cells with stem cell‑like properties in cancer (cancer stem 
cells) has been noted (26,27). A member of the T-box 
family, Brachyury, which appears to be regulated by the 
β-catenin oncogene, can induce the expression of stemness 
markers, such as NANOG, CD133, CD166 and CD44, in a 
subpopulation of colorectal cancer cells that mimic invasive 
front mesenchymal‑like cells (28). This transcription factor 
may be useful in predicting the outcome of chemotherapy 
and radiotherapy, as cancer stem cells are resistant to these 
treatments, and could become a target for specific therapies. 
A similar course may also occur in ovarian carcinoma and 
TBX15 may have a role in this process.
In conclusion, the data obtained in the present study 
supports the hypothesis that epigenetic alteration of the 
TBX15 gene is implicated in the pathogenesis of the majority 
of cases of ovarian carcinoma. The current data also suggests 
that TBX15, which is implicated in the development of meso-
derm-derived organs, such as the female reproductive system, 
may have a role in the neoplastic ovarian process, independent 
of the histological subtype. Therefore, hypermethylation of 
TBX15 may represent a potential biomarker for early detec-
tion, progression and response to treatments with a significant 
impact on reducing the mortality of this disease.
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